NATALEE + a slew of FDA updates
Update: 2024-09-26
Description
FDA has been busy the last week approving:
-ribociclib x 3 years in high risk stage II & III breast cancer based on the NATALEE trial as well as a new storage requirement
-osimertinib indefinitely following chemoradiation in stage III EGFR-mutated NSCLC
-amivantamab + chemotherapy following progression on osimertinib (Mariposa-2)
-a subcutaneous formulation of atezolizumab
-isatuximab + VRD for multiple myeloma
-pembrolizumab + chemotherapy for metastatic pleural mesothelioma
-ribociclib x 3 years in high risk stage II & III breast cancer based on the NATALEE trial as well as a new storage requirement
-osimertinib indefinitely following chemoradiation in stage III EGFR-mutated NSCLC
-amivantamab + chemotherapy following progression on osimertinib (Mariposa-2)
-a subcutaneous formulation of atezolizumab
-isatuximab + VRD for multiple myeloma
-pembrolizumab + chemotherapy for metastatic pleural mesothelioma
Comments
Top Podcasts
The Best New Comedy Podcast Right Now – June 2024The Best News Podcast Right Now – June 2024The Best New Business Podcast Right Now – June 2024The Best New Sports Podcast Right Now – June 2024The Best New True Crime Podcast Right Now – June 2024The Best New Joe Rogan Experience Podcast Right Now – June 20The Best New Dan Bongino Show Podcast Right Now – June 20The Best New Mark Levin Podcast – June 2024
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
